Serum levels of brain-derived neurotrophic factor in comorbidity of depression and alcohol dependence

Human Psychopharmacology

Volumn 24, Issue 5, 2009, Pages 409-413

  Umene Nakano, Wakako ^a   Yoshimura, Reiji ^a   Ikenouchi Sugita, Atsuko ^a   Hori, Hikaru ^a   Hayashi, Kenji ^a   Ueda, Nobuhisa ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Alcohol dependence; Brain derived neurotrophic factor; Depression

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FLUVOXAMINE; MILNACIPRAN; PAROXETINE; SERTRALINE; SULPIRIDE; ANTIDEPRESSANT AGENT;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE MARKER; DRUG RESPONSE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ANALYSIS OF VARIANCE; BLOOD; COMPARATIVE STUDY; DEPRESSION; IMMUNOASSAY; METHODOLOGY; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE;

ADULT; ALCOHOLISM; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COMORBIDITY; DEPRESSION; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES;

EID: 70149092155     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1035     Document Type: Article

References (32)

1. Altintoprak AE, Zorlu N, Coskunol H, Akdeniz F, Kitapcioglu G. 2008. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, doubleblind study. Hum Psychopharmacol 23: 313-319.
2. Aydemir C, Deveci A, Taneli F. 2005. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 29: 261-265.
3. Aydemir C, Yalcin ES, Aksaray S, et al. 2006. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog Neuropsychopharmacol Biol Psychiat 30: 1256-1260.
4. Bremner JD, Narayan M, Anderson ER, Straib LH, Miller HL, Charney DS. 2000. Hippocampal volume reduction in major depression. Am J Psychiatry 157: 115-118.
5. Drevetz WC, Price JL, Todd RD, Reich T, Vannier M, Raichle ME. 1997. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386: 824-827.
6. Drevetz WC. 2000. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 126: 413-431.
7. Durman RS, Heninger GR, Nestler EJ. 1997. A molecular and cellular theory of depression. Arch Gen Psychiatry 54: 597-606.
8. Duman RS, Malberg J, Nakagawa S, D' Sa C. 2000. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 48: 732-739.
9. Figurov A, Pozzo-Miller LD, Olafsson P, Wang T, Lu B. 1996. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 381: 706-709.
10. Gervasoni N, Aubry JM, Bondolfi G, et al. 2005. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 51: 234-238.
11. Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S. 2005. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 255: 381-386.
12. Joe KH, Kim YK, Kim TS, et al. 2007. Decreased plasma brain-derived neurotrophic factor levels in patients with alcohol dependence. Alcoholism Clin Exp Res 31: 1833-1838.
13. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. 2002. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109: 143-148.
14. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. 1997. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 54: 313-321.
15. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. 2005. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 593-602.
16. Korte M, Carrol P, Wolf E, Brem G, Thoenen H, Bonhoeffer T. 1995. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci USA 92: 8856-8860.
17. Manji HK, Drevets WC, Charney DS. 2001. The cellular neurobiology of depression. Nat Med 7: 541-547.
18. McAllister AK, Katz LC, Lo DC. 1999. Neurotrophins and synaptic plasticity. Ann Rev Neurosci 22: 295-318.
19. Mervaala E, Fohr J, Kononen M, et al. 2000. Quantitative MRI of the hippocampus and amygdale in severe depression. Psychol Med 30: 117-125.
20. Muhonen LH, Lonnqvist J, Juva K, Alho H. 2008. Double-blind, randomized comparison of memantine and escitaropram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 69: 392-399.
21. Pettinati HM. 2004. Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry 56: 785-792.
22. Radka SF, Holst PA, Fritsche M, Altar CA. 1996. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected and by a sensitive and specific immunoassay. Brain Res 709: 122-130.
23. Sapolsky RM. 2000. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57: 925-935.
24. Sen S, Duman R, Sanacora G. 2008. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analysis and implication. Biol Psychiatry 64: 527-532.
25. Shelton RC. 2000. Cellular mechanisms in the vulnerability to depression and response to antidepressants. Psychiatric Clin North Am 23: 713-729.
26. Shimizu E, Hashimoto K, Okuma N, et al. 2003. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54: 70-75.
27. Shinkai K, Yoshimura R, Ueda N, Okamoto K, Nakamura J. 2004. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 24: 11-17.
28. Shoval G, Weizman A. 2005. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 15: 319-329.
29. Thoenen H. 1995. Neurotrophins and neural plasticity. Science 270: 593-598.
30. Ueda N, Yoshimura R, Shinkai K, Nakamura J. 2002. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 35: 175-181.
31. Yoshimura R, Mitoma M, Sugita A, et al. 2007. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 31: 1034-1037.
32. Yoshimura R, Umene-Nakano W, Ueda N, Ikenouchi-Sugita A, Hori H, Nakamura J. 2008. Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline. Hum Psychopharmacol 23: 707-713.